Helicobacter pylori infection generated gastric cancer through p53-Rb tumor-suppressor system mutation and telomerase reactivation

Table 1 Expressions of c-myc, bcl-2, p53, Rb and hTERTmRNA in the different gastric diseases (%)

	GC	IMI-II	IMIII	DysI-II	DysIII	GC
c-myc	5 (11.90)	8 (17.39)	11 (44.00)	22 (45.83)	16 (59.26)	74 (88.09)
bcl-2	3 (7.14)	17 (36.96)	10 (40.00)	24 (50.00)	18 (66.67)	55 (65.48)
p53	0 (0.00)	3 (6.52)	5 (20.00)	14 (29.17)	10 (37.04)	64 (76.19)
Rb	3 (7.14)	4 (8.70)	8 (32.00)	14 (29.17)	12 (44.44)	61 (72.62)
HTERTmRNA	0 (0.00)	1 (2.17)	4 (16.00)	10 (16.67)	12 (44.44)	78 (92.86)

Table 2 The correlations between p53, Rb, c-myc, hTERT, bcl-2 and H. pylori in benign diseases and gastric cancer

H. pylori	CG		IMI-II		IMIII		DysI-II		DysIII		GC
	+(31)	-(11)	+(32)	-(14)	+(16)	-(9)	+(30)	-(18)	+(17)	-(10)	+(48)	-(36)
c-myc	5	0	7	1	10a	1	18a	4	13a	3	44	30
bcl-2	3	0	12	5	9a	1	17	7	13	5	38	17
p53	0	0	2	1	3	2	12a	2	6	4	39	25
Rb	3	0	4	0	6	2	11	3	9	3	40a	21
P53-Rb	3	0	4	1	6	3	21a	4	15a	3	48a	28
hTERT	0	0	1	0	4	0	8	2	9	3	47a	30

^aP < 0.05 vs the non-infected group.

Table 3 Correlation between c-myc and hTERT in the gastric benign diseases and gastric cancer

c-myc	CG		IMI-II		IMIII		DysI-II		DysIII		GC
	(+)	(-)	(+)	(-)	(+)	(-)	(+)	(-)	(+)	(-)	(+)	(-)
hTERT(+)	0	0	1	0	3	1	7	3	10a	2	70a	7
(-)	5	37	7	39	8	13	15	23	6	9	4	3

^aP < 0.05 vs the negative group.